Mankind Pharma licenses insulin analogues from Chenan

Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., a China-based biopharmaceutical company, to commercialize two insulin analogues in India: Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart. The agreement, announced on August 20, 2026, is part of Mankind Pharma's strategy to strengthen its presence in the diabetes care segment and expand its portfolio of injectable therapies. The partnership builds on Mankind Pharma's earlier collaborations for insulin products and reflects its focus on leveraging global innovation through strategic partnerships and in-licensing opportunities. Atish Majumdar, Senior President of Sales and Marketing at Mankind Pharma, highlighted China's emergence as a hub for innovative biopharmaceutical assets and the company's commitment to expanding its in-licensing pipeline from China. The deal is expected to enhance access to advanced therapies for Indian patients and reinforce Mankind Pharma's position in the injectable diabetes segment. Following the announcement, Mankind Pharma's shares opened 1.4% higher on the BSE, though they later retreated from the opening level.